NFL Biosciences Aims to Rewire Brain to Beat Nicotine Addiction

MONTPELLIER, France – April 07, 2026 – French biopharmaceutical company NFL Biosciences is pioneering a potential paradigm shift in the fight against nicotine addiction. The company recently unveiled the novel mechanism of its drug candidate, NFL-102, a botanical extract designed not just to manage withdrawal symptoms, but to fundamentally reverse the neurological changes that keep smokers hooked. This new approach targets the deep-seated roots of addiction in the brain, offering new hope in a market where relapse remains a significant challenge.

Unlike existing treatments that primarily focus on satisfying cravings or blocking nicotine's effects, NFL-102 is engineered to act on the underlying biology of addiction. The company released a video illustrating how the drug works, aiming to make the complex science accessible and underscore a strategy that could reshape addiction therapy.

A New Paradigm in Addiction Treatment

The core innovation of NFL-102 lies in its unique mechanism of action, which moves beyond the standard practice of targeting nicotinic receptors. Current therapies, including nicotine replacement patches and gums, varenicline (Chantix), and bupropion (Zyban), primarily work to lessen the discomfort of withdrawal. While helpful for many, their long-term success rates are hampered by high instances of relapse, as they do not address the profound, lasting changes nicotine inflicts on brain circuitry.

NFL-102 operates on a different level. Research, supported by studies from the French Alternative Energies and Atomic Energy Commission (CEA), shows the drug acts "downstream" of the nicotine receptors. It modulates key intracellular signaling pathways that become dysregulated by chronic nicotine use. Specifically, it targets two critical areas:

• The CREB Regulator: NFL-102 has been shown to reduce the activity of the CREB (cAMP response element-binding protein) signaling pathway. CREB is a central player in brain plasticity, the process by which neural circuits are reorganized. In addiction, this plasticity becomes maladaptive, creating powerful, ingrained pathways that drive compulsive drug-seeking behavior. By normalizing CREB activity, NFL-102 aims to undo this addiction-related "rewiring" and restore more normal brain function.

• Astrogliosis: The drug also appears to combat astrogliosis, a process involving reactive changes in brain cells called astrocytes. Once seen as simple support cells for neurons, astrocytes are now understood to play an active role in addiction. Chronic nicotine exposure can cause these cells to change in ways that reinforce addictive neural circuits. NFL-102 has been shown to decrease markers of this reactive state, suggesting it can mitigate the neuro-glial impact of smoking and help weaken the biological foundation of relapse.

This dual-action approach represents a fundamental shift from symptom management to a restorative therapy, aiming to return the addicted brain to a more pre-addicted state, thereby making sustained cessation more achievable.

From Lab to Clinic: The Path Forward

With a promising and distinct mechanism of action, NFL Biosciences is advancing NFL-102 through a structured clinical development pathway. The company has announced plans to initiate a Phase 2b clinical trial in mid-2026. This study is slated to enroll 450 participants in France to confirm the drug's efficacy, determine the optimal dosage, and further establish its safety profile.

The development of NFL-102 benefits from the company's work on its other lead candidate, NFL-101. While NFL-102 is an enriched formulation designed for broader action, NFL-101 has already generated promising clinical data. A 2023 trial, PRECESTO, demonstrated NFL-101's ability to reduce smoking satisfaction. Results from a larger Phase 2 trial, CESTO II, are anticipated in mid-2024, which will further inform the company's strategy.

Preclinical studies for NFL-102 have been successful, showing no signs of toxicity even at doses 600 times higher than those planned for clinical use. This strong safety signal, combined with its botanical origins as a nicotine-depleted tobacco leaf extract, positions it as a potentially safer alternative for a wide range of smokers.

Disrupting a Multi-Billion Dollar Market

The global market for smoking cessation and nicotine de-addiction therapies is substantial and growing, projected to exceed $70 billion by 2033. This growth is fueled by increasing public health awareness and a persistent, unmet need for more effective treatments. Despite the availability of several therapies, the journey to quitting smoking is notoriously difficult, and the high rate of relapse underscores the limitations of current options.

NFL-102 enters this landscape as a potential disruptor. By addressing the neurobiological persistence of addiction rather than just the acute symptoms of withdrawal, it could offer the durable efficacy that has long been the holy grail of cessation treatments. If clinical trials validate its ability to sustainably reduce relapse, it could capture a significant share of the market.

The company's strategic focus on intellectual property further strengthens its position. A new patent application filed for NFL-102 extends protection until 2047. Crucially, this patent also broadens the potential application of the drug's mechanism to other substance use disorders, including addiction to alcohol, opioids, and cannabinoids. This is based on the central role the CREB signaling pathway plays across various forms of addiction, opening up vast future opportunities for the platform.

The Science and Strategy Behind the Botanical Drug

NFL Biosciences’ approach is bolstered by collaborations with esteemed scientific institutions, lending significant credibility to its innovative claims. The partnership with the CEA has been instrumental in elucidating the complex mechanisms of both NFL-101 and NFL-102. The CEA's intent to submit the findings for publication in a peer-reviewed international journal signals confidence in the data and will be a critical step toward validation by the global scientific community.

Further collaborations, including a planned study with McLean Hospital, a top-ranked psychiatric hospital affiliated with Harvard Medical School, will continue to deepen the understanding of the drug's pharmacological profile. This commitment to rigorous scientific validation sets the company apart and builds a strong foundation for regulatory review and eventual market acceptance.

By developing a natural, botanical drug, NFL Biosciences also taps into a growing preference for plant-based therapeutics. The ambition is to provide a safer, more effective, and easy-to-administer option for the millions worldwide struggling to break free from nicotine. As research continues to unravel the complex brain science of addiction, therapies like NFL-102 that aim to heal the underlying neurological changes may represent the next frontier in treatment.